Oral composition

Abstract

To provide an oral composition for alleviating eye disorders.SOLUTION: An oral composition containing α - lipoic acid, an oral composition containing lutein and α - lipoic acid, a composition for improving the flavor of lutein, and an oral composition containing lutein and seaberry are prepared. Further, a method for improving the flavor of lutein and a method for improving the aggregation of lipoic acid are also provided. The oral composition containing α - lipoic acid is, for example, an oral composition for maintaining the amount of pigment in the macular region of the eye, maintaining the visual power, improving the contrast sensitivity of the eye, improving the focus adjustment of the eye, alleviating eye trouble, improving the condition of the eye, alleviating eye fatigue, improving accommodation failure, protecting the eye from light stimulation, or taking measures against blue light and liquid crystal light.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to an oral composition, and more particularly to an oral composition comprising lutein and α-lipoic acid, lutein and seaberry, or α-lipoic acid. [Background technology]

[0002] In recent years, with the changing lifestyles and the increasing elderly population, the number of people complaining of eye fatigue and eye problems has been increasing. To address this, a wide range of products have been developed, including eye drops, products that provide a warming or cooling sensation, and eye massagers.

[0003] Causes of eye fatigue and discomfort include overuse of the eyes due to reading, staring, observing, etc., mental stress, and aging. However, eye fatigue and discomfort are also common due to the rapid increase in VDT ​​(Visual Display Terminal) work that has occurred with the spread of personal computers and smartphones. Patients who complain of eye fatigue and discomfort generally also experience other symptoms such as pain behind the eyes, blurred vision, dry eyes, stiff shoulders, and a heavy head. It has been pointed out that these symptoms are caused by excessive tension in the ciliary muscles due to long periods of staring, which reduces the eye's ability to accommodate.

[0004] Age-related accommodation dysfunction and focus loss can be caused by presbyopia, cataracts, glaucoma, and age-related macular degeneration, but visual impairment and problems can occur even when these conditions or diseases are not the cause. Visual impairment can reduce quality of life (QOL), making it necessary to maintain and improve visual function.

[0005] To alleviate these symptoms, various eye drops and supplements have been developed. Lutein has been reported as an ingredient that is effective in improving contrast sensitivity, which is one of the visual functions (Patent Document 1).

[0006] In addition, lutein, astaxanthin, anthocyanins, and the like are known as ingredients used in compositions aimed at improving eye health and as ingredients with excellent effects in improving eye fatigue (e.g., Patent Documents 2 to 3).

[0007] [Patent Document 1] Special Publication No. 2013-501706 [Patent Document 2] Japanese Patent Application Laid-Open No. 2003-238442 [Patent Document 3] Japanese Patent Application Laid-Open No. 2005-287376 Summary of the Invention [Problem to be solved by the invention]

[0008] An object of the present invention is to provide an oral composition that has the effect of alleviating various eye disorders. [Means for solving the problem]

[0009] As a result of extensive research into developing an oral composition that has the effect of alleviating eye disorders, the inventors discovered that α-lipoic acid has the function of improving focus accommodation and maintaining close-range vision, and further discovered that α-lipoic acid and seaberry have the effect of improving the flavor of lutein, leading to the completion of the present invention.

[0010] That is, the present invention relates to the following compositions and methods. Section 1. An oral composition containing lutein and alpha-lipoic acid. Section 2. Item 2. The oral composition according to Item 1, comprising lutein and α-lipoic acid, wherein the parts by mass of α-lipoic acid per part by mass of lutein is 0.01 to 100 parts by mass. Section 3. A composition for improving the flavor of lutein containing α-lipoic acid. Section 4. A method for improving the flavor of an oral composition, comprising adding alpha-lipoic acid to the oral composition containing lutein. Section 5. A method for inhibiting aggregation of an oral composition, comprising allowing lutein to coexist in an oral composition containing α-lipoic acid. Section 6. An oral composition containing alpha-lipoic acid that maintains the amount of pigment in the macular region of the eye, maintains visual acuity, improves eye contrast sensitivity, improves eye focusing, relieves eye problems, improves eye condition, relieves eye fatigue, improves eye dysregulation, protects the eyes from light irritation, or provides protection from blue light and LCD light. Section 7. An oral composition containing α-lipoic acid for maintaining the amount of macular pigment that decreases with age, maintaining visual acuity that decreases with age, improving the decrease in contrast sensitivity of the eye due to age, improving the decrease in eye focusing function due to age, alleviating eye problems due to age, improving the eye condition due to age, alleviating eye fatigue due to age, or improving dysacralization due to age. Section 8. Item 8. The oral composition according to Item 6 or 7, further comprising lutein. Section 9. Item 9. The oral composition according to any one of Items 6 to 8, which contains lutein and α-lipoic acid, and the parts by mass of α-lipoic acid per part by mass of lutein is 0.01 to 10 parts by mass. Section 10. An oral composition containing lutein and seaberry. Section 11. Item 11. The oral composition according to Item 10, which contains lutein and seaberry, wherein the parts by mass of seaberry per part by mass of lutein is 0.1 to 100 parts by mass. Section 12. A composition for improving the flavor of lutein, containing seaberry. Section 13. A method for improving the flavor of an oral composition, comprising adding sea berry to the oral composition containing lutein. [Effects of the Invention]

[0011] According to the present invention, an oral composition that can relieve eye disorders and has a good taste can be provided. DETAILED DESCRIPTION OF THE INVENTION

[0012] (definition) As used herein, "flavor" refers to any sensation, such as aroma, smell, odor, or taste, that occurs when an oral composition is brought close to the nose or taken to the mouth. "Smell" also includes unpleasant odors experienced after eating or drinking an oral composition, such as aftertaste. "Flavor improvement" as used herein includes preventing deterioration of flavor over time, maintaining flavor over time, improving flavor compared to lutein alone, or enhancing flavor compared to lutein alone.

[0013] The "lutein" (β,ε-carotene-3,3'-diol) used in the present invention is a type of carotenoid present in plant leaves, flowers, fruits, etc. The lutein used in the present invention is not limited, but plant-derived lutein, particularly marigold-derived lutein, can be used. Lutein can also be incorporated by using marigold pigment itself. Alternatively, lutein derived from chloroplasts of spinach, kale, komatsuna, etc. can also be used. Lutein may be artificially synthesized, obtained by genetic recombination, or a commercially available product. Lutein may be in the form of a pharmaceutically acceptable salt.

[0014] Lutein is a reddish-orange pigment that accumulates in the macula of the retina and possesses antioxidant properties. The macula is a place where light energy is concentrated, and the dense cells there make it prone to oxidative stress accumulation due to their activity. However, macular pigments such as lutein, zeaxanthin, and meso-zeaxanthin protect against light exposure and oxidative stress, protecting visual function. Therefore, administration of lutein suppresses oxidative stress accumulation in retinal neurons, contributing to neuronal survival and visual function, and suppressing abnormal cell activity caused by excessive light exposure, the accumulation of oxidative stress in retinal photoreceptors, and cell death due to DNA damage. Lutein intake reduces the risk of developing age-related macular degeneration and cataracts. Administration of lutein improves contrast sensitivity in mesopic vision under high glare environments, improves contrast sensitivity in high mesopic vision conditions, and improves visual function under low lighting; it is also expected to delay ocular aging, maintain ocular function, and suppress the occurrence of retinal diseases such as age-related macular degeneration, retinitis pigmentosa, central chorioretinopathy, macular epithelial dystrophy, and macular hole.

[0015] Although lutein is a component with excellent functions, it is susceptible to decomposition by light or heat. Lutein also has an unpleasant taste or odor. Lutein-containing preparations suffer from problems such as flavor deterioration after storage and an unpleasant taste when consumed. Even soft capsules containing lutein stably suffer from problems such as a runny smell and an unpleasant taste after consumption.

[0016] The "α-lipoic acid" used in the present invention is represented by the following chemical formula:

[0017] [ka]

[0018] The α-lipoic acid in the present invention may be any of R,S-(+ / -)-α-lipoic acid, R-(+)-α-lipoic acid, and S-(-)-α-lipoic acid, and may also be a salt.

[0019] The α-lipoic acid in the present invention may be a synthetic or natural extract, or may be a commercially available product. The α-lipoic acid may be in the form of a powder, emulsion, or dispersion. The α-lipoic acid of the present invention may also be, but is not limited to, a cyclodextrin inclusion complex, from the viewpoint of significantly exhibiting the effects of the present invention.

[0020] As used herein, "aggregation" particularly refers to a phenomenon in which α-lipoic acid is not dispersed, and refers to a phenomenon in which, for example, components that settle upon centrifugation are generated.

[0021] In this specification, the term "oral composition" may refer to a composition that is used as it is as a food or drink, oral medicine, or oral quasi-drug, or may be used as a raw material for the production of these.

[0022] In this specification, the term "food and drink" includes food preparations and beverages such as functional foods, foods for specified health uses, foods with nutrient function claims, foods for the elderly, foods for special dietary uses, dietary supplements, or confectionery tablets. These may be in the form of supplement preparations, and include packaged beverages; beverages such as instant powdered drinks, instant granular drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juices that are dissolved in water (hot water), milk, fruit juice, and green juice; frozen desserts such as ice cream, iced sherbet, and shaved ice; noodles such as soba, udon, vermicelli, Chinese noodles, and instant noodles; sweets such as candy, candy, gum, chocolate, tablet sweets, snacks, biscuits, jellies, jams, creams, baked goods, and bread; and kamaboko. processed seafood and livestock foods such as ham and sausage; dairy products such as processed milk, fermented milk, and yogurt; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing, and processed foods thereof; condiments such as sauces and soy sauce; retort pouch foods such as curry, stew, oyakodon, porridge, rice porridge, Chinese rice bowl, katsudon, tempura bowl, beef bowl, hayashi rice, omelet rice, oden, mapo dolphin, gyoza, shumai, hamburger steak, meatballs, various sauces, and various soups.

[0023] (pH) When the oral composition of the present invention is in the form of a liquid, a beverage, or a liquid filled in a capsule, the pH is not particularly limited, but from the viewpoint of improving the flavor, it is preferably 2.0 to 8.0, more preferably 2.5 to 7.0, and even more preferably 3.0 to 6.0.

[0024] [Oral composition containing lutein and α-lipoic acid] A first aspect of the present invention relates to an oral composition containing lutein and α-lipoic acid.

[0025] The lutein content in the oral composition of the present invention containing lutein and α-lipoic acid is generally preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and even more preferably 1% by mass or more, based on the total amount of the composition. Within this range, a reasonably ingestible amount of lutein in the oral composition is sufficient to achieve the desired effect. Furthermore, the lutein content in the oral composition is preferably 30% by mass or less, more preferably 20% by mass or less, and even more preferably 10% by mass or less, based on the total amount of the composition. Within this range, the composition is easy to formulate and relatively easy to take.

[0026] The content of lutein in the oral composition of the present invention containing lutein and α-lipoic acid is generally preferably 0.01 to 30% by mass, more preferably 0.1 to 20% by mass, and even more preferably 1 to 10% by mass, based on the total amount of the composition.

[0027] When the oral composition containing lutein and α-lipoic acid of the present invention is in the form of a packaged beverage or liquid, the lutein content is preferably 0.001% by mass or more, more preferably 0.003% by mass or more, based on the total amount of the composition, and the lutein content in the packaged beverage or liquid is preferably 0.1% by mass or less, more preferably 0.025% by mass or less, based on the total amount of the composition.

[0028] When the oral composition of the present invention containing lutein and α-lipoic acid is in the form of a packaged beverage or liquid, the lutein content is preferably 0.001 to 0.1% by mass, and more preferably 0.003 to 0.025% by mass, based on the total amount.

[0029] Lutein may be administered in any amount effective for regulating eye condition, for example, preferably 0.1 mg to 50 mg per day, more preferably 1 mg to 30 mg, and even more preferably 6 mg to 25 mg.

[0030] The content of α-lipoic acid in the oral composition containing lutein and α-lipoic acid of the present invention is generally preferably 0.001% by mass or more, more preferably 0.01% by mass or more, and even more preferably 0.1% by mass or more, based on the total amount of the composition. Within this range, a reasonably ingestible amount of α-lipoic acid is contained in the oral composition to sufficiently achieve the desired effect. Furthermore, the content of α-lipoic acid in the oral composition is preferably 90% by mass or less, more preferably 50% by mass or less, and even more preferably 40% by mass or less, based on the total amount of the composition. Within this range, the composition is easy to formulate and relatively easy to take.

[0031] The content of α-lipoic acid in the oral composition of the present invention containing lutein and α-lipoic acid is generally preferably 0.001 to 90% by mass, more preferably 0.01 to 50% by mass, and even more preferably 0.1 to 40% by mass, based on the total amount of the composition.

[0032] When the oral composition containing lutein and α-lipoic acid of the present invention is in the form of a packaged beverage or liquid, the content of α-lipoic acid is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, based on the total amount of the composition, and the content of α-lipoic acid in the packaged beverage or liquid is preferably 1% by mass or less, more preferably 0.1% by mass or less, based on the total amount of the composition.

[0033] When the oral composition of the present invention containing lutein and α-lipoic acid is in the form of a packaged beverage or liquid preparation, the α-lipoic acid content is preferably 0.001 to 1% by mass, more preferably 0.005 to 0.1% by mass, based on the total amount.

[0034] The amount of α-lipoic acid may be sufficient to improve the flavor of lutein, but may also be contained in an amount that also functions to regulate eye condition, as described below. For example, the daily dose is preferably 1 mg to 1000 mg, more preferably 5 mg to 800 mg, and even more preferably 10 mg to 600 mg.

[0035] (ratio of each component) In the oral composition of the present invention containing lutein and α-lipoic acid, the content of α-lipoic acid per 1 part by mass of lutein is not particularly limited, but from the viewpoint of significantly improving the flavor of lutein and suppressing the aggregation of α-lipoic acid, it is preferably 0.01 to 100 parts by mass, more preferably 0.05 to 50 parts by mass, even more preferably 0.1 to 10 parts by mass, and particularly preferably 0.5 to 5 parts by mass.

[0036] (Other ingredients) The oral composition containing lutein and α-lipoic acid of the present invention may contain known ingredients other than lutein and α-lipoic acid that can be used in foods, beverages, pharmaceuticals, and quasi-drugs, as long as the effects of the present invention are not impaired. These include, but are not limited to, pH adjusters, preservatives, antioxidants (vitamin C, vitamin E, extracted tocopherol, etc.), thickeners, stabilizers, various colorants such as caramel color, emulsifiers, thickeners, and various other excipients, as well as active ingredients mainly derived from plants.

[0037] The type of emulsifier that can be used in the oral composition of the present invention containing lutein and α-lipoic acid is not particularly limited, and examples thereof include sucrose fatty acid esters, glycerin fatty acid esters (e.g., monoglycerin fatty acid esters, polyglycerin fatty acid esters, polyglycerin condensed ricinoleic acid esters, organic acid monoglycerides, etc.), propylene glycol fatty acid esters, sorbitan fatty acid esters, lecithin, enzymatically hydrolyzed lecithin, enzymatically treated lecithin, sodium stearoyl lactylate, calcium stearoyl lactylate, Quillaja extract, saponin, polysorbate, etc. These emulsifiers may be used alone or in combination of two or more.

[0038] The type of excipient used in the oral composition of the present invention containing lutein and α-lipoic acid is not particularly limited, and examples thereof include modified starch, starch hydrolysates (dextrin, powdered sugar, etc.), polysaccharides such as cellulose, sugars (monosaccharides (glucose, fructose, etc.), disaccharides (sucrose, lactose, maltose, trehalose, etc.), oligosaccharides (cellooligosaccharides, maltooligosaccharides, fructooligosaccharides, etc.), sugar alcohols (xylitol, sorbitol, lactitol, maltitol, etc.), reduced sugars, etc.), and dietary fiber (indigestible dextrin, polydextrose, enzymatic hydrolysates of guar gum, etc.). These excipients may be used alone or in combination of two or more.

[0039] The oral composition of the present invention containing lutein and α-lipoic acid can also contain carotenoids other than lutein. Examples of such carotenoids include crocetin, pharmaceutically acceptable salts of crocetin, gardenia extract (Zanzibara zirconia), gardenia pigment, saffron extract, germinated broccoli extract, broccoli sprout extract, paprika extract, β-carotene, zeaxanthin, astaxanthin, marigold extract, red paprika, paprika pigment, ginseng extract, chili pepper extract, eucommia leaf extract, safflower extract, and rafuma extract. The names in parentheses are alternative names. These carotenoids may be used alone or in combination of two or more.

[0040] The oral composition of the present invention containing lutein and α-lipoic acid can also contain polyphenols. Examples of polyphenols contained in the oral composition of the present invention containing lutein and α-lipoic acid include ginkgo biloba extract, mangosteen extract, strawberry seed extract, walnut polyphenol, guarana extract, Java ginger extract, nobiletin, blueberry leaf extract, black currant extract, curcumin, white curcuminoid, parsley extract, maqui berry extract, and polymethoxyflavonoid (PMF). These polyphenols may be used alone or in combination of two or more.

[0041] The oral composition of the present invention containing lutein and α-lipoic acid may also contain haskap juice, bilberry fruit extract, grape bud extract, ginger extract, etc. These may be used alone or in combination of two or more.

[0042] (Application) An oral composition containing lutein and α-lipoic acid is an oral composition that is easy to take, with the unpleasant taste caused by lutein either improved or enhanced. Furthermore, for example, but not limited to, in functional food products and health foods, it can be used to maintain the amount of pigment in the macular region of the eye, maintain visual acuity, improve eye contrast sensitivity, improve eye focus, relieve eye troubles, improve eye condition, relieve eye fatigue, improve dysaccadic eye function, protect the eye from light irritation, or protect against blue light and LCD light.

[0043] The oral composition of the present invention can be taken regardless of gender or age, and can also be used by patients with illnesses. It is particularly desirable for healthy individuals who are concerned about their eye condition to take it. For example, it is desirable for individuals who use their eyes for long periods of time, such as using a computer, doing desk work, or reading, to take it. The oral composition of the present invention can also be used for eye problems in middle-aged and elderly people, and can be used to maintain the amount of macular pigment that decreases with age, maintain visual acuity that decreases with age, improve contrast sensitivity that decreases with age, improve the decrease in ocular focusing function that occurs with age, alleviate eye problems caused by age, improve the condition of eyes caused by age, alleviate eye fatigue caused by age, or improve accommodation dysfunction caused by age. It is also desirable for individuals who have difficulty seeing small letters or objects, have difficulty seeing letters or objects close to them, have difficulty seeing in dim light, or have difficulty focusing on objects at different distances to take it.

[0044] (form) The oral composition of the present invention can be prepared in the form of, for example, solid dosage forms such as capsules, tablets, orally disintegrating tablets, granules, fine granules, pills, pastes, creams, caplets, gels, chewables, etc., or liquid dosage forms such as syrups and suspensions, as well as supplements and ordinary foods and beverages, etc. From the viewpoints of dosage and flavor, the oral composition of the present invention is preferably administered in the form of a solid dosage form in a capsule formulation.

[0045] When the oral composition of the present invention is prepared as a capsule formulation, it may be in the form of a hard capsule, soft capsule, microcapsule, seamless capsule, etc. The capsule shell is preferably composed of one or more of pigskin gelatin, pig bone gelatin, fish gelatin, or natural hydrophilic polymers. These capsule shells can be prepared by well-known conventional methods.

[0046] The capsule shell used in the capsule formulation may contain gelatin derived from animals or plants, natural polymers, thickening polysaccharides, and optionally oils and fats, polyhydric alcohols, surfactants, antioxidants, colorants, fragrances, etc.

[0047] The oral composition of the present invention can be stored as a daily dose in one container or divided into, for example, two or three containers in order to adjust the daily intake amount.

[0048] (Manufacturing method) The method for producing an oral composition containing lutein and α-lipoic acid of the present invention includes a step of incorporating lutein and α-lipoic acid.

[0049] In the step of incorporating lutein and α-lipoic acid, lutein and α-lipoic acid may be incorporated simultaneously or separately. When incorporated separately, the order of incorporation is not important.

[0050] The production of the oral composition of the present invention may further include a heat sterilization step, a container filling step, and the like.

[0051] [Lutein flavor improving composition containing α-lipoic acid] A second aspect of the present invention is a composition for improving the flavor of lutein, which contains α-lipoic acid. The composition for improving the flavor of lutein of the present invention contains α-lipoic acid.

[0052] In the flavor improving composition of the present invention, the content of α-lipoic acid is not particularly limited, but from the viewpoint of significantly exhibiting the effects of the present invention, it is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, even more preferably 0.01% by mass or more, particularly preferably 0.05% by mass or more, and most preferably 0.1% by mass or more, relative to the total amount of the flavor improving composition.

[0053] In the flavor improving composition of the present invention, the content of α-lipoic acid is not particularly limited, but from the viewpoint of significantly exhibiting the effects of the present invention, it may be preferably 100% by mass based on the total amount of the flavor improving composition, and may optionally contain other components.

[0054] In the flavor improving composition of the present invention, the content of α-lipoic acid is generally preferably 0.001 to 100% by mass, more preferably 0.005 to 100% by mass, even more preferably 0.01 to 100% by mass, particularly preferably 0.05 to 100% by mass, and most preferably 0.1 to 100% by mass, relative to the total amount of the composition.

[0055] The flavor-improving composition of the present invention can be used by being present together with an oral composition containing lutein.

[0056] The amount of α-lipoic acid may be sufficient to improve the flavor of lutein, but may also be contained in an amount that also functions to regulate eye condition, as described below. For example, the daily dose is preferably 1 mg to 1000 mg, more preferably 5 mg to 800 mg, and even more preferably 10 mg to 600 mg.

[0057] (Application) The lutein flavor-improving composition of the present invention, which contains α-lipoic acid, can be used as a raw material for producing foods and drinks, pharmaceuticals, or quasi-drugs, mainly to coexist with lutein.

[0058] (Other ingredients) Other ingredients used in the flavor improving composition of the present invention are the same as those described in the above section [Oral composition containing lutein and α-lipoic acid].

[0059] (form) The flavor improving composition of the present invention is not particularly limited in form, and may be in liquid, solid, or semi-solid form, and may be used as a material for preparing supplements in solid dosage forms such as tablets, orally rapidly disintegrating tablets, capsules, granules, fine granules, pills, pastes, creams, caplets, gels, and chewable tablets, or in liquid dosage forms such as syrups and suspensions.

[0060] [Method for improving the flavor of an oral composition containing lutein] The method of improving taste of the present invention is used for oral compositions containing lutein and comprises including α-lipoic acid in the composition.

[0061] The types and amounts of lutein and α-lipoic acid, as well as other ingredients, used in the flavor-improving method of the present invention are all similar to those described above in the section [Oral composition containing lutein and α-lipoic acid].

[0062] [Method for inhibiting aggregation of an oral composition containing α-lipoic acid] The aggregation-inhibiting method of the present invention is used for an oral composition containing α-lipoic acid, and comprises including lutein in the composition.

[0063] The types and amounts of lutein and α-lipoic acid used in the aggregation inhibition method of the present invention, as well as other ingredients, all conform to the contents described above in the section [Oral composition containing lutein and α-lipoic acid].

[0064] [Oral composition containing alpha-lipoic acid for improving eye condition] The present invention also relates to an oral composition containing α-lipoic acid for regulating eye condition, which can be used, for example, as a functional food or health food, to maintain the amount of pigment in the macular region of the eye, maintain visual acuity, improve contrast sensitivity, improve eye focus, relieve eye discomfort, improve eye condition, relieve eye fatigue, improve accommodation dysfunction, protect the eyes from light irritation, or protect against blue light or LCD light, for example, but is not limited to,

[0065] The oral composition of the present invention can be taken regardless of gender or age, and can also be used by patients with illnesses. It is particularly desirable for healthy individuals who are concerned about their eye condition to take it. For example, it is desirable for individuals who use their eyes for long periods of time, such as using a computer, doing desk work, or reading, to take it. The oral composition of the present invention can also be used for eye problems in middle-aged and elderly people, and can be used to maintain the amount of macular pigment that decreases with age, maintain visual acuity that decreases with age, improve contrast sensitivity that decreases with age, improve the decrease in ocular focusing function that occurs with age, alleviate eye problems caused by age, improve the condition of eyes caused by age, alleviate eye fatigue caused by age, or improve accommodation dysfunction caused by age. It is also desirable for individuals who have difficulty seeing small letters or objects, have difficulty seeing letters or objects close to them, have difficulty seeing in dim light, or have difficulty focusing on objects at different distances to take it.

[0066] (α-lipoic acid) The content of α-lipoic acid in the oral composition containing α-lipoic acid of the present invention is generally preferably 0.001% by mass or more, more preferably 0.01% by mass or more, and even more preferably 0.1% by mass or more, based on the total amount of the composition. Within this range, a reasonably ingestible amount of α-lipoic acid is contained in the oral composition to sufficiently achieve the desired effect. Furthermore, the content of α-lipoic acid in the oral composition is preferably 90% by mass or less, more preferably 50% by mass or less, and even more preferably 40% by mass or less, based on the total amount of the composition. This range facilitates formulation and relatively easy administration. The amount of α-lipoic acid may also be any amount effective for regulating eye condition.

[0067] The content of α-lipoic acid in the oral composition containing α-lipoic acid of the present invention is generally preferably 0.001 to 90% by mass, more preferably 0.01 to 50% by mass, and even more preferably 0.1 to 40% by mass, relative to the total amount of the composition.

[0068] When the oral composition containing α-lipoic acid of the present invention is a packaged beverage or liquid, the content of α-lipoic acid is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, based on the total amount of the composition, and the content of α-lipoic acid in the packaged beverage or liquid is preferably 1% by mass or less, more preferably 0.1% by mass or less, based on the total amount of the composition.

[0069] When the oral composition containing α-lipoic acid of the present invention is a packaged beverage or liquid preparation, the α-lipoic acid content is preferably 0.001 to 1 mass % and more preferably 0.005 to 0.1 mass % of the total amount, calculated as dry mass.

[0070] The daily dose of α-lipoic acid is, for example, preferably 1 mg to 1000 mg, more preferably 5 mg to 800 mg, and even more preferably 10 mg to 600 mg.

[0071] (lutein) The oral composition of the present invention containing α-lipoic acid may further contain lutein, which can further delay ocular aging and maintain ocular function.

[0072] The lutein content of the oral composition containing α-lipoic acid of the present invention is generally preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and even more preferably 1% by mass or more, based on the total amount of the composition. Within this range, a reasonably ingestible amount of lutein in the oral composition is sufficient to achieve the desired effect. Furthermore, the lutein content of the oral composition is preferably 30% by mass or less, more preferably 20% by mass or less, and even more preferably 10% by mass or less, based on the total amount of the composition. Within this range, the composition is easy to formulate and relatively easy to take.

[0073] The content of lutein in the oral composition of the present invention containing α-lipoic acid is generally preferably 0.01 to 30% by mass, more preferably 0.1 to 20% by mass, and even more preferably 1 to 10% by mass, based on the total amount of the composition.

[0074] When the oral composition containing α-lipoic acid of the present invention is a packaged beverage or liquid, the lutein content is preferably 0.001% by mass or more, more preferably 0.003% by mass or more, based on the total amount of the composition, and the lutein content in the packaged beverage or liquid is preferably 0.1% by mass or less, more preferably 0.025% by mass or less, based on the total amount of the composition.

[0075] When the oral composition of the present invention containing lutein and α-lipoic acid is in the form of a packaged beverage or liquid, the lutein content is more preferably 0.001 to 0.1 mass%, and even more preferably 0.003 to 0.025 mass%, of the total amount, calculated on a dry mass basis.

[0076] Lutein may also be contained in any amount effective for regulating eye condition, for example, preferably 0.1 mg to 50 mg per day, more preferably 1 mg to 30 mg, and even more preferably 6 mg to 25 mg.

[0077] Other ingredients, production method, and form of the oral composition containing α-lipoic acid of the present invention are all the same as those described in the above section [Oral composition containing lutein and α-lipoic acid].

[0078] (ratio of each component) When lutein is contained in the oral composition containing α-lipoic acid of the present invention, the content of α-lipoic acid per 1 part by mass of lutein is not particularly limited, but from the viewpoint of significantly exhibiting the effects of the present invention, it is preferably 0.01 to 100 parts by mass, more preferably 0.05 to 50 parts by mass, even more preferably 0.1 to 10 parts by mass, and particularly preferably 0.5 to 5 parts by mass.

[0079] [Oral composition containing lutein and seaberry] A third aspect of the present invention relates to an oral composition containing lutein and seaberry.

[0080] (lutein) The lutein content in the oral composition containing lutein and seaberry of the present invention is generally preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and even more preferably 1% by mass or more, based on the total amount of the composition. Within this range, a reasonably ingestible amount of lutein in the oral composition is contained, sufficient to provide the desired effects. Furthermore, the lutein content in the oral composition is preferably 30% by mass or less, more preferably 20% by mass or less, and even more preferably 10% by mass or less, based on the total amount of the composition. Within this range, the composition is easy to formulate and relatively easy to take.

[0081] The content of lutein in the oral composition containing lutein and seaberry of the present invention is generally preferably 0.01 to 30% by mass, more preferably 0.1 to 20% by mass, and even more preferably 1 to 10% by mass, relative to the total amount of the composition.

[0082] When the oral composition containing lutein and seaberry of the present invention is a packaged beverage or liquid, the lutein content is preferably 0.001% by mass or more, more preferably 0.003% by mass or more, based on the total amount of the composition. The lutein content in the packaged beverage or liquid is preferably 0.1% by mass or less, more preferably 0.025% by mass or less, based on the total amount of the composition.

[0083] When the oral composition containing lutein and seaberry of the present invention is a packaged beverage or liquid, it preferably contains 0.001 to 0.1% by mass, and even more preferably 0.003 to 0.025% by mass of lutein, calculated as dry mass, relative to the total amount.

[0084] Lutein may be administered in any amount effective for regulating eye condition, for example, preferably 0.1 mg to 50 mg per day, more preferably 1 mg to 30 mg, and even more preferably 6 mg to 25 mg.

[0085] (Seabury) Seaberry (Hippophae rhamnoides), also known as sea buckthorn, is a plant of the Elaeaceae family. In the present invention, seaberry includes, but is not limited to, ground seaberry, seaberry extract, etc. In the present invention, seaberry is preferably derived from a fruit containing the peel, pulp, and seeds. Seaberry may be at least one species selected from the group consisting of Hippophae rhamnoides Leikora and Hippophae rhamnoides Habego.

[0086] As used herein, the term "seaberry extract" is not limited to any substance derived from natural ingredients. In this specification, however, the term encompasses oil obtained from the fruit of the seaberry plant, preferably containing oil-soluble components. For example, commercially available products such as seaberry fruit oil (Oryza Oil & Fat Chemical) can also be used. Seaberry oil can be obtained by squeezing the juice from crushed fruit, centrifuging the resulting crude oil, filtering the oil, and then vacuum drying it. The term "seaberry extract" also encompasses products obtained by extracting seaberry fruit or its juice. For example, commercially available products such as Seaberry Extract P (Oryza Oil & Fat Chemical), Seaberry Extract WSP (Oryza Oil & Fat Chemical), Seaberry Extract J (Oryza Oil & Fat Chemical), and Seaberry Extract Oil (Puredia) can also be used. Extracts from seaberry fruit can also be obtained by extracting crushed dried fruit with a solvent (e.g., aqueous ethanol, water, hexane, etc.) in an amount several times the weight of the fruit at room temperature, followed by solid-liquid separation. Furthermore, the form of "seaberry" may be any of liquid, emulsion, paste, solid, and powder.

[0087] Seaberry oil is rich in fatty acids, including palmitoleic acid, palmitic acid, oleic acid, linoleic acid, alpha-linolenic acid, and stearic acid.

[0088] In seaberry oil, the palmitoleic acid content is preferably 10 to 60 mass%, more preferably 15 to 55 mass%, even more preferably 20 to 50 mass%, particularly preferably 25 to 45 mass%, and most preferably 30 to 40 mass%.

[0089] In seaberry oil, the palmitic acid content is preferably 10 to 60 mass%, more preferably 15 to 55 mass%, even more preferably 20 to 50 mass%, particularly preferably 25 to 45 mass%, and most preferably 30 to 40 mass%.

[0090] In seaberry oil, the content of oleic acid is preferably 5 to 55 mass%, more preferably 10 to 50 mass%, even more preferably 15 to 45 mass%, particularly preferably 20 to 40 mass%, and most preferably 25 to 35 mass%.

[0091] In the oil-soluble fraction of seaberry, the content ratio of palmitoleic acid, palmitic acid, and oleic acid is not particularly limited as long as the effects of the present invention are achieved, but it is preferable that the mass ratio be, for example, 1:0.5-2:0.2-2, more preferably 1:0.8-1.5:0.5-1.5, and even more preferably 1:0.8-1.2:0.5-1.2.

[0092] The content of seaberry (including seaberry extract) in the oral composition containing lutein and seaberry of the present invention may vary depending on the form of the oral composition. Generally, the content is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and even more preferably 0.1% by mass or more, based on the total amount of the composition, calculated on a dry weight basis. Within this range, a reasonably ingestible amount of seaberry extract sufficient to achieve the desired effect is contained in the oral composition. Furthermore, the content of α-lipoic acid in the oral composition is preferably 50% by mass or less, more preferably 30% by mass or less, and even more preferably 10% by mass or less, based on the total amount of the composition, calculated on a dry weight basis. Within this range, the composition is easy to formulate and relatively easy to administer.

[0093] The seaberry extract is preferably 0.005% by mass or more, more preferably 0.02% by mass or more, even more preferably 0.07% by mass or more, and even more preferably 0.15% by mass or more, relative to the total amount of the composition. Within this range, a reasonably ingestible amount of seaberry is contained in the oral composition to adequately achieve the desired effect. Furthermore, the content of seaberry extract in the oral composition, converted to dry weight, is preferably 40% by mass or less, more preferably 20% by mass or less, and even more preferably 15% by mass or less, relative to the total amount of the composition. Within this range, formulation and administration are relatively easy.

[0094] Seaberry oil available as "seaberry oil" can also be used, preferably at 0.005% by mass or more, more preferably at 0.02% by mass or more, even more preferably at 0.07% by mass or more, and even more preferably at 0.15% by mass or more, based on the total amount of the composition. Within this range, a reasonably ingestible amount of seaberry will be contained in the oral composition to adequately achieve the desired effect. Furthermore, the content of seaberry oil in the oral composition, calculated as dry weight, is preferably 40% by mass or less, more preferably 20% by mass or less, and even more preferably 15% by mass or less, based on the total amount of the composition. Within this range, the composition is easy to formulate and relatively easy to administer.

[0095] The content of seaberry in the oral composition containing lutein and seaberry of the present invention is generally preferably 0.01 to 50% by mass, more preferably 0.05 to 30% by mass, and even more preferably 0.1 to 10% by mass, calculated as dry weight, relative to the total amount of the composition.

[0096] The content of seaberry extract in the oral composition containing lutein and seaberry of the present invention is generally, converted to dry weight, preferably 0.005 to 40% by mass, more preferably 0.02 to 15% by mass, even more preferably 0.07 to 10% by mass, and even more preferably 0.15 to 5% by mass, relative to the total amount of the composition.

[0097] The content of seaberry oil in the oral composition containing lutein and seaberry of the present invention is generally, converted to dry weight, preferably 0.005 to 40% by mass, more preferably 0.02 to 15% by mass, even more preferably 0.07 to 10% by mass, and even more preferably 0.15 to 5% by mass, relative to the total amount of the composition.

[0098] When the oral composition containing lutein and seaberry of the present invention is a packaged beverage or liquid, the seaberry content, converted to dry weight, is preferably 0.0001% by mass or more, more preferably 0.0002% by mass or more, and even more preferably 0.001% by mass or more, of the total amount. Furthermore, the seaberry content, converted to dry weight, in the packaged beverage or liquid is preferably 10% by mass or less, more preferably 5% by mass or less, and even more preferably 1% by mass or less, of the total amount of the composition.

[0099] When the oral composition containing lutein and seaberry of the present invention is a packaged beverage or liquid, the content of seaberry extract is preferably 0.00005% by mass or more, more preferably 0.0001% by mass or more, and even more preferably 0.0005% by mass or more, based on the total amount. Furthermore, the content of seaberry in the packaged beverage or liquid, converted to dry weight, is preferably 10% by mass or less, more preferably 5% by mass or less, and even more preferably 1% by mass or less, based on the total amount of the composition.

[0100] When the oral composition containing lutein and seaberry of the present invention is a packaged beverage or liquid, the content of seaberry oil is preferably 0.00005% by mass or more, more preferably 0.0001% by mass or more, and even more preferably 0.0005% by mass or more, based on the total amount. The content of seaberry in the packaged beverage or liquid, converted to dry weight, is preferably 10% by mass or less, more preferably 5% by mass or less, and even more preferably 1% by mass or less, based on the total amount of the composition.

[0101] Seaberry may be contained in an amount sufficient to improve the flavor of lutein, but may also be contained in an amount that also functions to regulate eye condition, as described below. For example, the daily intake is preferably 0.1 mg to 200 mg, more preferably 0.5 mg to 100 mg, and even more preferably 1 mg to 10 mg.

[0102] Seaberry may be contained in an amount sufficient to improve the flavor of lutein, but may also be contained in an amount that also has the function of regulating eye condition, as described below. For example, the amount of seaberry extract per day is preferably 0.1 mg to 200 mg, more preferably 0.5 mg to 100 mg, and even more preferably 1 mg to 10 mg.

[0103] Seaberry oil may be contained in an amount sufficient to improve the flavor of lutein, but may also be contained in an amount that also has the function of regulating eye condition, as described below. For example, the amount of seaberry oil per day is preferably 0.1 mg to 200 mg, more preferably 0.5 mg to 100 mg, and even more preferably 1 mg to 10 mg.

[0104] (ratio of each component) In the oral composition of the present invention containing lutein and seaberry, the content of seaberry per 1 part by mass of lutein is not particularly limited, but from the viewpoint of significantly improving the flavor of lutein and inhibiting the aggregation of α-lipoic acid, the content is usually 0.01 to 100 parts by mass, preferably 0.1 to 100 parts by mass, more preferably 0.1 to 50 parts by mass, even more preferably 0.1 to 10 parts by mass, and particularly preferably 0.5 to 5 parts by mass, calculated as dry mass or seaberry oil.

[0105] The other ingredients, manufacturing method, uses, and form of the oral composition containing lutein and seaberry of the present invention are all the same as those described in the above section [Oral composition containing lutein and α-lipoic acid].

[0106] The present invention also includes the following aspects. (1) Use of alpha-lipoic acid to manufacture an oral composition for maintaining the amount of pigment in the macular region of the eye, maintaining visual acuity, improving contrast sensitivity of the eye, improving eye focusing, alleviating eye discomfort, improving eye condition, alleviating eye fatigue, improving dysaccadic eye function, protecting the eye from light irritation, or for countermeasures against blue light and LCD light or alleviating symptoms. (2) Use of alpha-lipoic acid to produce an oral composition for maintaining the amount of macular pigment that decreases with age, maintaining visual acuity that decreases with age, improving age-related decreases in contrast sensitivity of the eye, improving age-related decreases in eye focusing function, alleviating eye problems caused by age, improving age-related eye condition, alleviating age-related eye fatigue, or improving age-related accommodation dysfunction. (3) The use of (1) or (2) above, in which lutein is used in addition to alpha-lipoic acid. [Example]

[0107] The present invention will be described below based on examples.

[0108] [Test Example 1] Lutein's flavor-improving effect The taste-improving effect of lutein was evaluated. The oral compositions of Example 1 and Comparative Example 1 shown in Table 1 were mixed to prepare a composition. Five taste judges took approximately 50 mg of each oral composition with a spatula and evaluated the taste felt immediately after taking it. The taste score was rated on a scale of 0 to 15, with 15 representing "unbearable to take" and 0 representing "able to take," and the values ​​of the five judges were averaged. However, the judges were unable to tell whether the oral composition was from the Example or Comparative Example, and the evaluation was carried out in a manner that prevented them from recognizing it. The judges used a scale of 0 to 15 based on the following criteria to standardize the perception of the values. The higher the value, the stronger the unpleasant flavor felt and the greater the difficulty in taking the medicine. 0: Can be taken 1: I can take it, but the taste and smell are a bit bothersome. 2: I can take it, but the taste and smell are a bit bothersome. 3: I can take it, but I'm concerned about the taste and smell. 4: It is possible to take it, but the taste and smell are a bit bothersome. 5: It is possible to take it, but the taste and smell are a bit bothersome 6: It is possible to take it, but the taste and smell are bothersome 7: It is possible to take it, but the taste and smell are quite bothersome. 8: I don't want to take it too much 9: I would rather not take it if possible 10: I don't want to take it 11: I really don't want to take it 12: I want to avoid taking it 13: I want to avoid taking it as much as possible 14: I would like to avoid taking medicine unless absolutely necessary. 15: I can't tolerate it

[0109] [Table 1]

[0110] [Test Results] The test results are shown in Table 2. [Table 2]

[0111] It was confirmed that the oral composition of Comparative Example 1 had a very unpleasant taste due to lutein, resulting in very poor compliance with administration. It was confirmed that the oral composition of Example 1 had an improved taste score, resulting in an improved usability.

[0112] [Test Example 2] Lutein inhibits aggregation of α-lipoic acid 10 mg of each oral composition from Example 2 and Comparative Example 2 shown in Table 3 was collected and filled into a 30 mL glass bottle (screw cap), and 10 mL of safflower oil was added and dispersed. Centrifugation (3100 rpm; 10 minutes) was performed using a refrigerated centrifuge (EX-126, manufactured by Tomy Seiko Co., Ltd.), and 1 mL of the supernatant was collected before and after centrifugation. Each sample was then diluted to a measurable concentration, and the α-lipoic acid content was measured by HPLC. The α-lipoic acid content was measured by HPLC using a reverse-phase column (CAPCELL PAK C18, manufactured by Osaka Soda Co., Ltd.) and quantitatively analyzed at a wavelength of 330 nm using an ultraviolet spectrophotometer. The aggregation inhibition rate (%) of each sample was calculated from the obtained content value using the following formula 1. Formula 1: α-lipoic acid aggregation inhibition rate (%) = (content after centrifugation) / (content before centrifugation) × 100

[0113] [Test Results] The test results are shown in Table 3.

[0114] [Table 3]

[0115] When the oral composition of Comparative Example 1 was centrifuged, α-lipoic acid aggregated and settled, and was not uniformly dispersed. Therefore, the α-lipoic acid aggregation inhibition rate was low. In the oral composition of Example 2, lutein did not aggregate after centrifugation, maintaining good dispersibility, and the α-lipoic acid aggregation inhibition rate was high. The results of this test confirmed that α-lipoic acid has the effect of inhibiting lutein aggregation.

[0116] [Test Example 3] Alpha-lipoic acid's effect on alleviating eye disorders The effect of α-lipoic acid on alleviating eye disorders was evaluated. The oral compositions of Example 3 and Reference Example shown in Table 4 were mixed and prepared into soft capsules. These were administered once daily for four weeks, and the change in near visual acuity (average of eight subjects) and change in near point (average of four subjects) between before and after administration were evaluated. Near visual acuity was measured using a Hiragana International Near Point Test Chart (Near Visual Acuity Chart) (Handaya Shoten), and near visual acuity was determined based on the size of characters legible by the subject at a distance of 30 cm. Near point measurement was performed using a Triiris C9000 (Hamamatsu Photonics K.K.), and the position at which the subject saw a blurred target was recorded as the near point. Note that all measurements were performed after the subjects had undergone a visual acuity test and corrected their vision beforehand.

[0117] [Table 4]

[0118] The mass % ratio of cyclodextrin to α-lipoic acid in the R-α-lipoic acid-CD inclusion complex used was 88.5:11.5.

[0119] The results of the change in near visual acuity and near point are shown in Table 4. These results demonstrate that α-lipoic acid improves near visual acuity and is useful for focusing.

[0120] Furthermore, a questionnaire survey was conducted on the difficulty of focusing on objects close to the subject before and after taking the oral composition of the Examples or Reference Examples once a day for four weeks. Evaluation was performed using the VAS (Visual Analogue Scale) method, with the leftmost score (score 0) representing "I can focus on objects close to the subject without any problems" and the rightmost score (score 100) representing "It is extremely difficult to focus on objects close to the subject." The difference in scores before and after intake for each of the four subjects was averaged. The following results were obtained for the four subjects. In the Examples, the average score was negative, indicating that it became easier to focus on objects close to the subject.

[0121] [Table 5]

[0122] [Test Example 4] Lutein's flavor-improving effect The taste-improving effect of lutein was evaluated. The oral compositions of Example 5 and Comparative Example 3 shown in Table 6 were mixed to prepare the composition. Five taste judges evaluated the taste felt immediately after taking approximately 50 mg of each oral composition with a spatula. The taste score was rated on a scale of 0 to 15, with 15 representing "unbearable to take" and 0 representing "able to take," and the values ​​of the five judges were averaged. That is, the scale rating from 0 to 15 was based on the following criteria, and the judges shared a common understanding of the values. The higher the value, the stronger the unpleasant flavor felt and the greater the degree of difficulty in taking the composition. 0: Can be taken 1: I can take it, but the taste and smell are a bit bothersome. 2: I can take it, but the taste and smell are a bit bothersome. 3: I can take it, but I'm concerned about the taste and smell. 4: It is possible to take it, but the taste and smell are a bit bothersome. 5: It is possible to take it, but the taste and smell are a bit bothersome 6: It is possible to take it, but the taste and smell are bothersome 7: It is possible to take it, but the taste and smell are quite bothersome. 8: I don't want to take it very often 9: I don't want to take it if possible 10: I don't want to take it 11: I really don't want to take it 12: I want to avoid taking it 13: I want to avoid taking it as much as possible 14: I would like to avoid taking medicine unless absolutely necessary. 15: I can't tolerate the medication

[0123] [Table 6]

[0124] The seaberry oil used contained 30.1% by mass of palmitoleic acid, 30% by mass of palmitic acid, 28.6% by mass of oleic acid, 2.8% by mass of linoleic acid, 1.00% by mass of α-linolenic acid, and 0.6% by mass of stearic acid.

[0125] [Test Results] The test results are shown in Table 7. [Table 7]

[0126] It was confirmed that the oral composition of Comparative Example 3 had a very unpleasant taste due to lutein, resulting in very poor compliance with administration. It was confirmed that the oral compositions of the Examples had improved taste scores, resulting in improved usability.

[0127] Formulation examples of oral compositions containing lutein and α-lipoic acid, lutein and seaberry, or α-lipoic acid according to the present invention are shown below. All of these can be used as oral compositions for maintaining macular pigment levels, maintaining visual acuity, improving ocular contrast sensitivity, improving ocular accommodation, alleviating eye discomfort, improving eye condition, alleviating eye fatigue, improving accommodation dysfunction, protecting the eyes from light irritation, or protecting against blue light and LCD light. Alternatively, they can be used as oral compositions for maintaining macular pigment levels that decrease with age, maintaining visual acuity that decreases with age, improving ocular contrast sensitivity that decreases with age, improving ocular accommodation function that decreases with age, alleviating eye discomfort, improving eye condition, alleviating eye fatigue, or improving accommodation dysfunction that occurs with age. These compositions are also recommended for individuals who have difficulty seeing small letters or objects, those who have difficulty seeing letters or objects close to them, those who have difficulty seeing in dim light, and those who take a long time to focus on objects at different distances.

[0128] [Formulation example] [Table 8]

[0129] [Table 9]

[0130] [Table 10] Here, powdered beverage means a powder that can be dissolved in 100 to 200 ml of water (3 g).

[0131] [Table 11]

[0132] [Table 12]

Claims

1. An oral composition containing lutein and α-lipoic acid, wherein the mass parts of α-lipoic acid per mass part of lutein is 0.1 to 10 mass parts. (However, (1) a composition in which the composition ratio (by weight) of each component of the raw material portion is 0.05 to 10% lutein, 10 to 80% taurine, 0.001 to 0.01% selenium, 1 to 20% α-lipoic acid, 1 to 10% L-ascorbic acid, 0.01 to 1% β-carotene, 0.0001 to 0.001% DHEA, 1 to 10% grape seed extract, and 0.01 to 1% pyridoxine hydrochloride; (2) a composition in which the composition ratio (by weight) of each component of the raw material portion is 0.5 to 1.5 parts by weight of α-lipoic acid, 5 to 15 parts by weight of lutein, and coenzyme Q10 (3) a composite preparation with anti-radiation and vision protection functions, which is composed of the following by weight: tea seed oil: 65-98%; coenzyme Q10: 0.15-15.0%; lutein: 0.05-10.0%; α-lipoic acid: 0.10-10.0%; and vitamin A: 0.01-0.10%; (4) a nutritional or dietary composition in a daily dosage, in which α-lipoic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, ascorbic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, and α-tocopherol or (5) a composition for oral administration for treating age-related macular degeneration, wherein vitamin C is present in an amount of 250 mg to 700 mg, zinc is present in an amount of 10 mg to 150 mg, copper is present in an amount of 0.5 mg to 4 mg, alpha-lipoic acid is present in an amount of 10 mg to 30 mg, lutein is present in an amount of 1 mg to 40 mg, bilberry is present in an amount of 10 mg to 200 mg, grape seed extract is present in an amount of 1 mg to 40 mg, L-glutathione is present in an amount of 1 mg to 100 mg, zeaxanthin is present in an amount of 1 mg to 10 mg, vitamin B-6 is present in an amount of 1 mg to 40 mg, and selenium is present in an amount of 100 mcg to 300 mcg;(6) Excluding dietary supplements containing a daily dose of 3750-6250 IU of vitamin A, 300-500 IU of vitamin E, 30-50 mg of zinc, 187.5-312.5 mg of vitamin C, 300-500 mg of bilberry, 1.5-2.5 mg of copper, 150-250 mg of selenium, 300-500 mg of taurine, 15-25 mg of alpha-lipoic acid, 9-15 mg of lutein, 2.25-3.75 mg of zeaxanthin, 45-75 mg of grape seed extract, 15-25 mg of vinpocetine, 22.5-37.5 mg of lycopene, and 45-75 mg of ginkgo biloba (24%).

2. A method for improving the flavor of an oral composition, comprising allowing α-lipoic acid to coexist in an oral composition containing lutein, wherein the mass parts of α-lipoic acid per mass part of lutein is 0.1 to 10 mass parts (provided that the oral composition is one of the following: (1) a composition in which the composition ratios (by weight) of each component of the raw material portion are lutein 0.05 to 10%, taurine 10 to 80%, selenium 0.001 to 0.01%, α-lipoic acid 1 to 20%, L-ascorbic acid 1 to 10%, β-carotene 0.01 to 1%, DHEA 0.0001 to 0.001%, grape seed extract 1 to 10%, and pyridoxine hydrochloride 0.01 to 1%; (2) a composition in which the composition ratios (by weight) of each component of the raw material portion are lutein 0.5 to 1.5 parts by weight, lutein 5 to 15 parts by weight, and coenzyme Q10 (3) a composite preparation with anti-radiation and vision protection functions, which is composed of the following by weight: tea seed oil: 65-98%, coenzyme Q10: 0.15-15.0%, lutein: 0.05-10.0%, α-lipoic acid: 0.10-10.0%, and vitamin A: 0.01-0.10 percent; (4) a nutritional or dietary composition in a daily dosage, in which α-lipoic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, ascorbic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, and α-tocopherol or its pharmaceutical equivalent is present in an amount of 50-1000 mg. (5) a composition for oral administration for treating age-related macular degeneration, wherein vitamin C is present in an amount of 250 mg to 700 mg, zinc is present in an amount of 10 mg to 150 mg, copper is present in an amount of 0.5 mg to 4 mg, α-lipoic acid is present in an amount of 10 mg to 30 mg, lutein is present in an amount of 1 mg to 40 mg, bilberry is present in an amount of 10 mg to 200 mg, grape seed extract is present in an amount of 1 mg to 40 mg, L-glutathione is present in an amount of 1 mg to 100 mg, zeaxanthin is present in an amount of 1 mg to 10 mg, vitamin B-6 is present in an amount of 1 mg to 40 mg, and selenium is present in an amount of 100 mcg to 300 mcg;(6) Excluding dietary supplements containing a daily dose of 3750-6250 IU of vitamin A, 300-500 IU of vitamin E, 30-50 mg of zinc, 187.5-312.5 mg of vitamin C, 300-500 mg of bilberry, 1.5-2.5 mg of copper, 150-250 mg of selenium, 300-500 mg of taurine, 15-25 mg of alpha-lipoic acid, 9-15 mg of lutein, 2.25-3.75 mg of zeaxanthin, 45-75 mg of grape seed extract, 15-25 mg of vinpocetine, 22.5-37.5 mg of lycopene, and 45-75 mg of ginkgo biloba (24%).

3. A method for inhibiting aggregation of α-lipoic acid in an oral composition, comprising allowing lutein to coexist in the oral composition containing α-lipoic acid, wherein the parts by mass of α-lipoic acid per part by mass of lutein is 0.1 to 10 parts by mass (provided that the oral composition is: (1) a composition in which the composition ratios (by weight) of each component of the raw material portion are 0.05 to 10% of lutein, 10 to 80% of taurine, 0.001 to 0.01% of selenium, 1 to 20% of α-lipoic acid, 1 to 10% of L-ascorbic acid, 0.01 to 1% of β-carotene, 0.0001 to 0.001% of DHEA, 1 to 10% of grape seed extract, and 0.01 to 1% of pyridoxine hydrochloride; or (2) a composition in which the composition ratios (by weight) of each component of the raw material portion are 0.5 to 1.5 parts by weight of α-lipoic acid, 5 to 15 parts by weight of lutein, and coenzyme Q10 (3) a composite preparation with anti-radiation and vision protection functions, which is composed of the following by weight: tea seed oil: 65-98%, coenzyme Q10: 0.15-15.0%, lutein: 0.05-10.0%, α-lipoic acid: 0.10-10.0%, and vitamin A: 0.01-0.10 percent; (4) a nutritional or dietary composition in a daily dosage, in which α-lipoic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, ascorbic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, and α-tocopherol or its pharmaceutical equivalent is present in an amount of 50-1000 mg. (5) a composition for oral administration for treating age-related macular degeneration, wherein vitamin C is present in an amount of 250 mg to 700 mg, zinc is present in an amount of 10 mg to 150 mg, copper is present in an amount of 0.5 mg to 4 mg, α-lipoic acid is present in an amount of 10 mg to 30 mg, lutein is present in an amount of 1 mg to 40 mg, bilberry is present in an amount of 10 mg to 200 mg, grape seed extract is present in an amount of 1 mg to 40 mg, L-glutathione is present in an amount of 1 mg to 100 mg, zeaxanthin is present in an amount of 1 mg to 10 mg, vitamin B-6 is present in an amount of 1 mg to 40 mg, and selenium is present in an amount of 100 mcg to 300 mcg;(6) Excluding dietary supplements containing a daily dose of 3750-6250 IU of vitamin A, 300-500 IU of vitamin E, 30-50 mg of zinc, 187.5-312.5 mg of vitamin C, 300-500 mg of bilberry, 1.5-2.5 mg of copper, 150-250 mg of selenium, 300-500 mg of taurine, 15-25 mg of alpha-lipoic acid, 9-15 mg of lutein, 2.25-3.75 mg of zeaxanthin, 45-75 mg of grape seed extract, 15-25 mg of vinpocetine, 22.5-37.5 mg of lycopene, and 45-75 mg of ginkgo biloba (24%).

4. An oral composition containing α-lipoic acid, for maintaining the amount of pigment in the macula of the eye, maintaining visual acuity, improving contrast sensitivity, improving eye focus, alleviating eye troubles, improving eye condition, alleviating eye fatigue, improving dysaccharin, protecting the eye from light irritation, or for protection against blue light and liquid crystal light (provided that (1) the composition ratio (wt%) of each component in the raw material portion is 0.05 to 10% by weight of lutein). %, taurine 10-80%, selenium 0.001-0.01%, α-lipoic acid 1-20%, L-ascorbic acid 1-10%, β-carotene 0.01-1%, DHEA 0.0001-0.001%, grape seed extract 1-10%, pyridoxine hydrochloride 0.01-1%; (2), α-lipoic acid 0.5-1.5 parts by weight, lutein 5-15 parts by weight, coenzyme Q10 (3) a composite preparation with anti-radiation and vision protection functions, which is composed of the following by weight: tea seed oil: 65-98%, coenzyme Q10: 0.15-15.0%, lutein: 0.05-10.0%, α-lipoic acid: 0.10-10.0%, and vitamin A: 0.01-0.10 percent; (4) a nutritional or dietary composition in a daily dosage, in which α-lipoic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, ascorbic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, and α-tocopherol or its pharmaceutical equivalent is present in an amount of 50-1000 mg. (5) a composition for oral administration for treating age-related macular degeneration, wherein vitamin C is present in an amount of 250 mg to 700 mg, zinc is present in an amount of 10 mg to 150 mg, copper is present in an amount of 0.5 mg to 4 mg, α-lipoic acid is present in an amount of 10 mg to 30 mg, lutein is present in an amount of 1 mg to 40 mg, bilberry is present in an amount of 10 mg to 200 mg, grape seed extract is present in an amount of 1 mg to 40 mg, L-glutathione is present in an amount of 1 mg to 100 mg, zeaxanthin is present in an amount of 1 mg to 10 mg, vitamin B-6 is present in an amount of 1 mg to 40 mg, and selenium is present in an amount of 100 mcg to 300 mcg;(6) Excluding dietary supplements containing a daily dose of 3750-6250 IU of vitamin A, 300-500 IU of vitamin E, 30-50 mg of zinc, 187.5-312.5 mg of vitamin C, 300-500 mg of bilberry, 1.5-2.5 mg of copper, 150-250 mg of selenium, 300-500 mg of taurine, 15-25 mg of alpha-lipoic acid, 9-15 mg of lutein, 2.25-3.75 mg of zeaxanthin, 45-75 mg of grape seed extract, 15-25 mg of vinpocetine, 22.5-37.5 mg of lycopene, and 45-75 mg of ginkgo biloba (24%).

5. An oral composition containing alpha-lipoic acid for maintaining the amount of macular pigment that decreases with age, maintaining visual acuity that decreases with age, improving age-related decline in contrast sensitivity, improving age-related decline in eye focusing function, alleviating age-related eye problems, improving age-related eye conditions, alleviating age-related eye fatigue, or improving age-related accommodation dysfunction. (However, (1) a composition in which the composition ratio (by weight) of each component of the raw material portion is lutein 0.05-10%, taurine 10-80%, selenium 0.001-0.01%, α-lipoic acid 1-20%, L-ascorbic acid 1-10%, β-carotene 0.01-1%, DHEA 0.0001-0.001%, grape seed extract 1-10%, pyridoxine hydrochloride 0.01-1%; (2) a composition in which the composition ratio (by weight) of each component of the raw material portion is lutein 0.05-10%, taurine 10-80%, selenium 0.001-0.01%, α-lipoic acid 1-20%, L-ascorbic acid 1-10%, β-carotene 0.01-1%, DHEA 0.0001-0.001%, grape seed extract 1-10%, pyridoxine hydrochloride 0.01-1%; (3) a composite preparation with anti-radiation and vision protection functions, which is composed of the following by weight: tea seed oil: 65-98%, coenzyme Q10: 0.15-15.0%, lutein: 0.05-10.0%, α-lipoic acid: 0.10-10.0%, and vitamin A: 0.01-0.10 percent; (4) a nutritional or dietary composition in a daily dosage, in which α-lipoic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, ascorbic acid or its pharmaceutical equivalent is present in an amount of 50-1000 mg, and α-tocopherol or its pharmaceutical equivalent is present in an amount of 50-1000 mg. (5) a composition for oral administration for treating age-related macular degeneration, wherein vitamin C is present in an amount of 250 mg to 700 mg, zinc is present in an amount of 10 mg to 150 mg, copper is present in an amount of 0.5 mg to 4 mg, α-lipoic acid is present in an amount of 10 mg to 30 mg, lutein is present in an amount of 1 mg to 40 mg, bilberry is present in an amount of 10 mg to 200 mg, grape seed extract is present in an amount of 1 mg to 40 mg, L-glutathione is present in an amount of 1 mg to 100 mg, zeaxanthin is present in an amount of 1 mg to 10 mg, vitamin B-6 is present in an amount of 1 mg to 40 mg, and selenium is present in an amount of 100 mcg to 300 mcg;(6) Excluding dietary supplements containing a daily dose of 3750-6250 IU of vitamin A, 300-500 IU of vitamin E, 30-50 mg of zinc, 187.5-312.5 mg of vitamin C, 300-500 mg of bilberry, 1.5-2.5 mg of copper, 150-250 mg of selenium, 300-500 mg of taurine, 15-25 mg of alpha-lipoic acid, 9-15 mg of lutein, 2.25-3.75 mg of zeaxanthin, 45-75 mg of grape seed extract, 15-25 mg of vinpocetine, 22.5-37.5 mg of lycopene, and 45-75 mg of ginkgo biloba (24%).

6. The oral composition according to claim 4 or 5, further comprising lutein.

7. The oral composition according to any one of claims 4 to 6, comprising lutein and α-lipoic acid, wherein the mass parts of lipoic acid per mass part of lutein is 0.1 to 10 mass parts.

Images